Theratechnologies Slumps 57.50% (LIVE, CSUN, BMTI, THER, GSV)
LiveDeal Inc (NASDAQ:LIVE) surged up 17.09% to $8.35 on a traded volume of 154k shares. So far this year, the stock is up over 109%. The 52-week range for the stock is $1.02 and $9.21. The Company has Price/Sales ratio of 4.68 and Price/Book ratio of 6.76. The 50-Day Moving Average and 200-Day Moving Average prices is $5.78 and $4.76 respectively.
China Sunergy Co Ltd (NASDAQ:CSUN) went up 19.02% to $2.19. Recently, China Sunergy Co Ltd announced that the Company has completed delivery of 5 Megawatt in solar modules to Bulgaria for the Yerussalimovo Solar Park. The modules were sold to Mitsubishi International GmbH and are being installed and managed by Helios Power. Helios Power has been a strategic partner for China Sunergy Co., Ltd. in Bulgarian market starting from 2010.
BioMimetic Therapeutics Inc (NASDAQ:BMTI) soared 6.35% to $3.35. Dr. Timothy Daniels announced the results of a Canadian registration study comparing Augment™ Injectable Bone Graft to autograft in foot and ankle fusion surgery. The trial met its primary endpoint of non-inferiority of AIBG to autograft as assessed by CT scan at six months.
Theratechnologies Inc (NASDAQ:THER) slipped 57.53% to $0.79. The Company announced important regulatory updates regarding the European Union, Canada and Brazil. Ferrer Internacional S.A., commercial partner of the Company is responsible for all regulatory filings in Europe. Ferrer Internacional S.A. is withdrawing the Marketing Authorization Application filed with the European Medicines Agency for tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.
Gold Standard Ventures Corporation Common Stock slipped 10.13% to $2.04. So far this year, the stock is down over 18%. The 52-week range for the stock is $0.63 and $3.05. The Company has entered into an underwriting agreement with Dahlman Rose & Co LLC to sell a total of 10 million common shares at a price of $2.00 per common share. The gross proceeds will be $20 million pursuant to a short form base PREP prospectus filed with the securities regulators. The Company has also granted an over-allotment option to the Underwriters to purchase up to an additional 1.5 million common shares at the offering price, exercisable at any time up to 30 days from the closing of the offering.